Innovative inhalation formulations for severe respiratory diseases

InhaTarget Therapeutics is a spin-off company from the University of Brussels (ULB) - Belgium, dedicated to the early development and clinical validation of innovative treatments of pulmonary diseases by inhalation, with a first focus on lung cancer. The company was established in August 2019 and brings together strong complementary expertise in drug formulation, inhalation delivery, immunology, preclinical development and clinical operations.

About Us

Technology

Clinical Trial

Inhatarget focuses on inhalation formulations to improve treatment for severe respiratory diseases.

Our mission

Change the game of existing molecules through novel and improved treatment modalities in terms of route of administration, frequency of treatment, mechanism of action, or compound stability.

Learn More

Our latest news

Follow our LinkedIn and stay up to date with our latest activities.

March 30, 2023

InhaTarget Therapeutics at the European Society for Medical Oncology European Lung Cancer Congress 2023

January 11, 2023

InhaTarget Therapeutics is featured in this article on inhalable drugs published in The Wall Street Journal

December 6, 2022

InhaTarget Therapeutics is present at The Drug Delivery to the Lungs (DDL) 2022 Conference in Edinburgh

View all

Innovative treatments by inhalation

Our mission

Our latest news

Innovative treatments
by inhalation